Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
Zura Bio (NASDAQ: ZURA) reported its full year 2024 financial results, highlighting significant operational and financial achievements. The company completed a $112.5 million private placement in April 2024, ending the year with $176.5 million in cash and cash equivalents, providing runway through 2027.
Key developments include initiating the Phase 2 TibuSURE trial for systemic sclerosis and plans to launch a Phase 2 study for hidradenitis suppurativa in Q2 2025. Financial results show R&D expenses decreased to $24.4 million from $44.0 million in 2023, while G&A expenses increased to $30.8 million from $18.6 million. The company reported a net loss of $45.4 million ($0.60 per share) compared to $69.2 million ($2.09 per share) in 2023.
Zura Bio (NASDAQ: ZURA) ha riportato i risultati finanziari dell'intero anno 2024, evidenziando significativi traguardi operativi e finanziari. L'azienda ha completato un collocamento privato di 112,5 milioni di dollari nell'aprile 2024, chiudendo l'anno con 176,5 milioni di dollari in cassa e equivalenti di cassa, garantendo così liquidità fino al 2027.
Tra i principali sviluppi vi è l'avvio della sperimentazione TibuSURE di Fase 2 per la sclerosi sistemica e i piani per lanciare uno studio di Fase 2 per l'idrosadenite suppurativa nel secondo trimestre del 2025. I risultati finanziari mostrano che le spese per R&S sono diminuite a 24,4 milioni di dollari rispetto ai 44,0 milioni di dollari del 2023, mentre le spese generali e amministrative sono aumentate a 30,8 milioni di dollari rispetto ai 18,6 milioni. L'azienda ha riportato una perdita netta di 45,4 milioni di dollari (0,60 dollari per azione) rispetto ai 69,2 milioni di dollari (2,09 dollari per azione) del 2023.
Zura Bio (NASDAQ: ZURA) informó sus resultados financieros del año completo 2024, destacando logros operativos y financieros significativos. La compañía completó un colocación privada de 112,5 millones de dólares en abril de 2024, cerrando el año con 176,5 millones de dólares en efectivo y equivalentes de efectivo, lo que proporciona liquidez hasta 2027.
Los desarrollos clave incluyen el inicio del ensayo TibuSURE de Fase 2 para la esclerosis sistémica y planes para lanzar un estudio de Fase 2 para la hidradenitis supurativa en el segundo trimestre de 2025. Los resultados financieros muestran que los gastos en I+D disminuyeron a 24,4 millones de dólares desde 44,0 millones de dólares en 2023, mientras que los gastos generales y administrativos aumentaron a 30,8 millones de dólares desde 18,6 millones. La compañía reportó una pérdida neta de 45,4 millones de dólares (0,60 dólares por acción) en comparación con 69,2 millones de dólares (2,09 dólares por acción) en 2023.
주라 바이오 (NASDAQ: ZURA)는 2024년 전체 연도 재무 결과를 발표하며 중요한 운영 및 재무 성과를 강조했습니다. 이 회사는 2024년 4월에 1억 1,250만 달러의 사모펀드 모집을 완료하고, 2027년까지 운영할 수 있는 1억 7,650만 달러의 현금 및 현금성 자산으로 연도를 마감했습니다.
주요 개발 사항으로는 전신 경화증에 대한 TibuSURE 2상 시험 시작과 2025년 2분기에 수포성 다한증에 대한 2상 연구를 시작할 계획이 포함됩니다. 재무 결과에 따르면 연구개발 비용은 2,440만 달러로 감소했으며, 이는 2023년 4,400만 달러에서 감소한 수치입니다. 반면, 일반 관리 비용은 3,080만 달러로 증가했으며, 이는 1,860만 달러에서 증가한 수치입니다. 회사는 4,540만 달러의 순손실을 보고했으며(주당 0.60달러), 이는 2023년의 6,920만 달러(주당 2.09달러)와 비교됩니다.
Zura Bio (NASDAQ: ZURA) a publié ses résultats financiers pour l'année complète 2024, mettant en avant des réalisations opérationnelles et financières significatives. L'entreprise a complété un placement privé de 112,5 millions de dollars en avril 2024, clôturant l'année avec 176,5 millions de dollars en liquidités et équivalents de liquidités, offrant ainsi une marge de manœuvre jusqu'en 2027.
Les développements clés incluent le lancement de l'essai TibuSURE de Phase 2 pour la sclérodermie et des projets de lancement d'une étude de Phase 2 pour l'hydradénite suppurative au deuxième trimestre 2025. Les résultats financiers montrent que les dépenses de R&D ont diminué à 24,4 millions de dollars contre 44,0 millions de dollars en 2023, tandis que les dépenses générales et administratives ont augmenté à 30,8 millions de dollars contre 18,6 millions. L'entreprise a déclaré une perte nette de 45,4 millions de dollars (0,60 dollar par action) par rapport à 69,2 millions de dollars (2,09 dollars par action) en 2023.
Zura Bio (NASDAQ: ZURA) hat seine Finanzberichte für das gesamte Jahr 2024 veröffentlicht und dabei bedeutende betriebliche und finanzielle Erfolge hervorgehoben. Das Unternehmen schloss im April 2024 eine Privatplatzierung in Höhe von 112,5 Millionen US-Dollar ab und beendete das Jahr mit 176,5 Millionen US-Dollar in Bargeld und Barmitteln, was bis 2027 finanziellen Spielraum bietet.
Zu den wichtigsten Entwicklungen gehört der Start der Phase-2-Studie TibuSURE für systemische Sklerose sowie die Pläne zur Einleitung einer Phase-2-Studie für Hidradenitis suppurativa im 2. Quartal 2025. Die finanziellen Ergebnisse zeigen, dass die F&E-Ausgaben auf 24,4 Millionen US-Dollar gesenkt wurden, von 44,0 Millionen US-Dollar im Jahr 2023, während die allgemeinen und Verwaltungskosten auf 30,8 Millionen US-Dollar anstiegen, von 18,6 Millionen US-Dollar. Das Unternehmen meldete einen Nettoverlust von 45,4 Millionen US-Dollar (0,60 US-Dollar pro Aktie) im Vergleich zu 69,2 Millionen US-Dollar (2,09 US-Dollar pro Aktie) im Jahr 2023.
- Cash position strengthened to $176.5M with runway through 2027
- Reduced net loss by 34% to $45.4M in 2024
- R&D expenses decreased by $19.6M to $24.4M
- Successfully raised $112.5M through private placement
- G&A expenses increased by $12.2M to $30.8M
- One-time non-cash stock-based compensation expense of $5.9M
- Additional $4.5M milestone payment required for tibulizumab license
Insights
Zura Bio's financial position has significantly strengthened with
The net loss improvement from
Concerning is the G&A expense increase of
The warrant exchange and ATM program establishment demonstrate financial maturity and flexibility. The extended cash runway reduces near-term financing risk, creating a stable foundation for clinical development through key data readouts. However, as a pre-revenue company with unproven clinical assets, Zura's fundamental value drivers remain tied to future clinical results rather than current financial metrics.
Zura Bio's clinical development strategy shows measured progress with the initiation of the Phase 2 TibuSURE trial for systemic sclerosis (SSc) and plans to launch a Phase 2 study for hidradenitis suppurativa (HS) in Q2 2025. The company is building a multi-indication pipeline for its lead asset tibulizumab, targeting serious autoimmune conditions with significant unmet needs.
The company's strategic leadership additions—particularly Dr. Kiran Nistala as CMO and the establishment of a scientific advisory board—strengthen their immunology expertise. These appointments typically indicate a transition from early discovery to a more mature clinical development organization preparing for later-stage trials.
Zura's approach to crebankitug demonstrates scientific prudence, continuing translational medicine research while collaborating with KOLs before committing to specific indications. For torudokimab, the strategy of monitoring competitor IL-33/ST2 data before determining their development path shows resource discipline and risk mitigation.
While the pipeline shows promise across multiple immunological pathways and indications, the absence of clinical efficacy data means the therapeutic potential remains theoretical. The cash runway through 2027 provides adequate funding for these planned trials and potential data readouts. For biotechnology investors, the most significant value inflection points lie ahead with the upcoming data from these Phase 2 programs, which will determine whether Zura's assets have meaningful clinical differentiation in highly competitive immunology markets.
- Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline
- Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc)
-
Completed a
private placement financing in April 2024, contributing to a total of$112.5 million in cash and cash equivalents, as of December 31, 2024$176.5 million - Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS)
“In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlighting our commitment to establishing a leading presence in immunology,” said Robert Lisicki, Chief Executive Officer of Zura Bio. “We remain dedicated to developing treatments for patients with severe autoimmune and inflammatory diseases. In 2025, we look forward to building on this progress with continued advancements, including our TibuSURE Phase 2 study for SSc and the anticipated launch of a Phase 2 study for HS in Q2.”
CORPORATE HIGHLIGHTS AND UPCOMING ANTICIPATED MILESTONES
Tibulizumab
Systemic sclerosis
In December 2024, Zura Bio advanced its clinical pipeline by initiating the Phase 2 TibuSURE trial in SSc.
Hidradenitis suppurativa
- In September 2024, a third-party Contract Research Organization was selected to oversee and conduct the Phase 2 clinical program for HS.
-
Zura Bio holds an active Investigational New Drug with the
U.S. Food and Drug Administration, allowing the clinical trial to proceed. - Zura Bio plans to initiate a Phase 2 trial for the treatment of adults with HS in the second quarter of 2025.
Crebankitug
- Zura Bio is exploring potential therapeutic applications where IL-7/TSLP inhibition may provide meaningful clinical and commercial benefits.
- Ongoing translational medicine research and collaborations with key opinion leaders aim to enhance the understanding of its clinical potential.
Torudokimab
Zura Bio is monitoring external Phase 2 and Phase 3 IL-33/ST2 data in asthma and chronic obstructive pulmonary disease to inform its development strategy.
Corporate Highlights
- In January 2024, Kiran Nistala, MBBS, PhD, a rheumatologist and immunologist, joined as Chief Medical Officer and Head of Development, further strengthening our clinical and scientific leadership.
-
In April 2024, Robert Lisicki was appointed Chief Executive Officer and played a key role in securing
through an oversubscribed private placement, supported by leading life sciences-focused institutional investors.$112.5 million - In June 2024, a Scientific Advisory Board was established, composed of leading specialists in rheumatology, dermatology, and immunology.
- In June 2024, data from two abstracts on tibulizumab in Sjögren’s syndrome and rheumatoid arthritis were presented at the Annual European Congress of Rheumatology.
- In August 2024, the Company successfully completed a warrant exchange, simplifying its capital structure.
- In September 2024, the Company established an "at-the-market" (ATM) program, providing increased financial flexibility.
FULL YEAR 2024 FINANCIAL RESULTS
Cash Position
Cash and cash equivalents were
Research and Development (R&D) Expenses
Research and development expenses were
General and Administrative (G&A) Expenses
General and administrative expenses were
Net Loss
Net Loss was
ABOUT ZURA BIO
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs.
FORWARD-LOOKING STATEMENTS
This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” “strategy,” “future,” “opportunity,” “would,” “seem,” “seek,” “outlook,” “goal,” “mission,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this communication. These forward-looking statements in this release include, but are not limited to, statements regarding: Zura Bio’s forecasts, including with respect to its cash resources; Zura Bio’s expectations regarding funding, operating and working capital expenditures, business strategies and objectives; expectations with respect to Zura Bio’s development program, including its product candidates and the potential benefits thereof, data readouts, regulatory matters, clinical trials and the design and timing thereof; expectations with respect to development programs, data readouts and product candidates of other parties. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.
Actual events are difficult or impossible to predict and could differ materially from those expressed or implied in such forward-looking statements, as a result of these risks and uncertainties, which include, but are not limited to: Zura Bio’s expectations regarding its product candidates and their related benefits, and Zura Bio’s beliefs regarding competing product candidates and products both in development and approved, may not be achieved; Zura Bio's vision and strategy may not be successful; the timing of key events and initiation of Zura Bio's studies, regulatory matters and release of clinical data may take longer than anticipated or may not be achieved at all; the potential general acceptability and maintenance of Zura Bio's product candidates by regulatory authorities, payors, physicians, and patients may not be achieved; Zura Bio's ability to attract and retain key personnel; Zura Bio's expectations with respect to its future operating expenses, capital requirements and needs for additional financing may not be achieved; Zura Bio has not completed any clinical trials, and has no products approved for commercial sale; Zura Bio has incurred significant losses since inception, and expects to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future; Zura Bio requires substantial additional capital to finance its operations, and if it is unable to raise such capital when needed or on acceptable terms, Zura Bio may be forced to delay, reduce, and/or eliminate one or more of its development programs or future commercialization efforts; Zura Bio may be unable to renew existing contracts or enter into new contracts; Zura Bio relies on third-party contract development manufacturing organizations for the manufacture of clinical materials; Zura Bio relies on contract research organizations, clinical trial sites, and other third parties to conduct of its preclinical studies and clinical trials; Zura Bio may be unable to obtain regulatory approval for its product candidates, and there may be related restrictions or limitations of any approved products; Zura Bio may be unable to successfully respond to general economic and geopolitical conditions; Zura Bio may be unable to effectively manage growth; Zura Bio faces competitive pressures from other companies worldwide; Zura Bio may be unable to adequately protect its intellectual property rights; and other factors set forth in documents filed, or to be filed by Zura Bio, with the Securities and Exchange Commission (SEC), including the risks and uncertainties described in the “Risk Factors” section of Zura Bio's Annual Report on Form 10-K for the year ended December 31, 2024 and other filings with the SEC. These risks and uncertainties may be amplified by health epidemics or other unanticipated global disruption events, which may continue to cause economic uncertainty. Zura Bio cautions that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Zura Bio gives no assurance that it will achieve its expectations. Zura Bio does not undertake or accept any obligation to update any forward-looking statements, except as required by law.
ZURA BIO LIMITED CONSOLIDATED BALANCE SHEETS (In thousands, except share data)
|
||||||||
December 31, |
||||||||
|
2024 |
|
|
|
2023 |
|
||
Assets |
|
|
|
|
||||
Current assets |
||||||||
Cash and cash equivalents |
|
$ |
176,498 |
|
|
$ |
99,806 |
|
Prepaid expenses and other current assets |
|
2,246 |
|
|
1,037 |
|
||
Total current assets |
|
|
178,744 |
|
|
|
100,843 |
|
Property and equipment, net |
|
91 |
|
|
– |
|
||
Other assets |
|
698 |
|
|
– |
|
||
Total assets |
|
$ |
179,533 |
|
|
$ |
100,843 |
|
Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity |
|
|
|
|
||||
Current liabilities |
||||||||
Accounts payable and accrued expenses |
|
$ |
19,514 |
|
|
$ |
20,302 |
|
Total current liabilities |
|
19,514 |
|
|
20,302 |
|
||
Private placement warrants |
|
|
– |
|
|
|
990 |
|
Total liabilities |
|
19,514 |
|
|
21,292 |
|
||
|
|
|
|
|
||||
Commitments and contingencies |
||||||||
|
|
|
|
|
||||
Redeemable noncontrolling interest |
|
11,663 |
|
|
18,680 |
|
||
|
|
|
|
|
||||
Shareholders’ Equity |
||||||||
Preferred shares, |
|
|
– |
|
|
|
– |
|
Class A Ordinary Shares, |
|
7 |
|
|
4 |
|
||
Additional paid-in capital |
|
|
302,705 |
|
|
|
162,820 |
|
Accumulated deficit |
|
(155,897 |
) |
|
(103,494 |
) |
||
Total Zura Bio Limited shareholders' equity |
|
|
146,815 |
|
|
|
59,330 |
|
Noncontrolling interest |
|
1,541 |
|
|
1,541 |
|
||
Total shareholders’ equity |
|
|
148,356 |
|
|
|
60,871 |
|
Total liabilities, redeemable noncontrolling interest and shareholders' equity |
$ |
179,533 |
|
$ |
100,843 |
|
ZURA BIO LIMITED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share data)
|
||||||||
For the Years Ended December 31, |
||||||||
|
2024 |
|
|
|
2023 |
|
||
Operating expenses: |
|
|
|
|
||||
Research and development | $ |
24,401 |
|
$ |
43,999 |
|
||
General and administrative |
|
|
30,788 |
|
|
|
18,639 |
|
Total operating expenses |
|
55,189 |
|
|
62,638 |
|
||
Loss from operations |
|
|
(55,189 |
) |
|
|
(62,638 |
) |
Other (income)/expense, net |
||||||||
Interest income |
|
|
(7,998 |
) |
|
|
(2,186 |
) |
Change in fair value of private placement warrants |
|
5,240 |
|
|
(724 |
) |
||
Change in fair value of note payable |
|
|
– |
|
|
|
2,244 |
|
Dividend income |
|
– |
|
|
(1,392 |
) |
||
Other income, net |
|
|
(28 |
) |
|
|
(17 |
) |
Total other income, net |
|
(2,786 |
) |
|
(2,075 |
) |
||
Loss before income taxes |
|
|
(52,403 |
) |
|
|
(60,563 |
) |
Income tax benefit |
|
– |
|
|
– |
|
||
Net loss before redeemable noncontrolling interest |
|
|
(52,403 |
) |
|
|
(60,563 |
) |
Net loss attributable to redeemable noncontrolling interest |
|
– |
|
|
203 |
|
||
Net loss |
|
|
(52,403 |
) |
|
|
(60,360 |
) |
Adjustment of redeemable noncontrolling interest from redemption value to carrying value |
|
7,017 |
|
|
– |
|
||
Accretion of redeemable noncontrolling interest to redemption value |
|
|
– |
|
|
|
(7,220 |
) |
Deemed contribution from redeemable noncontrolling interest |
|
– |
|
|
9,212 |
|
||
Deemed dividend to redeemable noncontrolling interest |
|
|
– |
|
|
|
(10,875 |
) |
Net loss attributable to Class A Ordinary Shareholders of Zura |
$ |
(45,386 |
) |
$ |
(69,243 |
) |
||
Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted |
|
$ |
(0.60 |
) |
|
$ |
(2.09 |
) |
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted |
|
75,070,761 |
|
|
33,064,036 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325942559/en/
Megan K. Weinshank
Head of Corporate Affairs
ir@zurabio.com
Source: Zura Bio Limited